Inhibition of human CYP3A4 and CYP3A5 enzymes by gomisin C and gomisin G, two lignan analogs derived from Schisandra chinensis

Jin Zhao(Shenyang Pharmaceutical University), Jun Yin(Shenyang Pharmaceutical University), Kun Yang(Fudan University), Zhong‐Ze Fang(Tianjin Medical University), Yongzhe Liu(Shandong University), Yun‐Feng Cao(Jinzhou Medical University), Frank J. Gonzalez(National Cancer Institute), Jingjing Wu(Army Medical University), Zhi‐Tu Zhu(First Affiliated Hospital of Liaoning Medical University), Tao Sun(Liaoning Cancer Hospital & Institute), Hongzhi Sun(First Affiliated Hospital of Xi'an Jiaotong University)
Fitoterapia
March 24, 2017
10.1016/j.fitote.2017.03.010
Cited by 23

Related Papers

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.
|Journal of Clinical Investigation|1998|406
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
|Journal of the American Society of Nephrology|2017|222
Bile salt hydrolase catalyses formation of amine-conjugated bile acids
|Nature|2024|204
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
|Diabetes|2010|187